Medical Oncology, Humanitas Clinical & Research Hospital, Rozzano, Italy.
Nuclear Medicine - Humanitas Cancer Center, Humanitas Clinical & Research Hospital, Via Manzoni 56, 20089 - Rozzano, Italy.
Immunotherapy. 2018 Jul;10(9):797-805. doi: 10.2217/imt-2017-0187.
The treatment algorithm of advanced non-small-cell lung cancer is rapidly evolving. This result is mostly related to the availability in clinical practice of checkpoint inhibitors targeting the programmed death-1 (PD-1) and its ligands (PD-Ls) immunosuppressive pathway. Although patient's selection in the first-line setting relies essentially on high levels of PD-L1 tumor expression, treatment choice in pretreated patients is more challenging and, although clinical and biological characteristics might be of help, there is an urgent need for novel tools to better identify sensitive and resistant patients. In this context, the integration of molecular markers and immune-PET imaging might represent a potentially effective strategy to refine patient selection.
晚期非小细胞肺癌的治疗方案正在迅速发展。这主要是由于临床实践中可应用针对程序性死亡受体-1（PD-1）及其配体（PD-Ls）免疫抑制途径的检查点抑制剂。尽管一线治疗中患者的选择主要依赖于高水平的 PD-L1 肿瘤表达，但在预处理患者中选择治疗方案更具挑战性，尽管临床和生物学特征可能有所帮助，但仍迫切需要新的工具来更好地识别敏感和耐药患者。在这种情况下，分子标志物与免疫 PET 成像的整合可能是一种有效的策略，可以完善患者选择。
